Find and Pitch Jounalists, Get Your Story Covered

Tags: DLBCL Diffuse Large B Cell Lymphoma Bispecific Antibodies DLBCL Trials toxicity management

	Profile	Recent Articles on Subject
1	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 4 days ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL - 8 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - 9 months ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study - 6 days ago
3	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances With Various Therapies Targeting DLL3 in Lung Neuroendocrine Tumors - 8 days ago GSK5764227 Receives Breakthrough Therapy Designation to Treat Extensive-Stage Small–Cell Lung Cancer - about 1 month ago FDA Grants Priority Review for Durvalumab to Treat Small Cell Lung Cancer - about 1 month ago Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer - 5 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 6 months ago Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC - 6 months ago Phase 3 EVOKE-01 Study in Metastatic NSCLC Falls Short of Primary Endpoint - 7 months ago
4	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 8 days ago Trial Questions Role of Dual Immunotherapy in First-Line NSCLC - 28 days ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 6 months ago Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results - 7 months ago Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC - 7 months ago Can ctDNA Guide Radiation Use in Oligometastatic NSCLC? - 12 months ago
5	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	'Very Clear Signal' That Survival Improved With Addition of Durvalumab in SCLC - 2 months ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 3 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 3 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 8 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - 8 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 9 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 9 months ago Positive Results for Odronextamab in Relapsed/Refractory DLBCL - 9 months ago The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer - 11 months ago
6	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Brentuximab Vedotin Shows 37% Reduction in Risk of Death for DLBCL - 3 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 6 months ago Samsung Bioepis Initiates Phase 1 Trial for Proposed Keytruda Biosimilar - 7 months ago
7	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 3 months ago FDA Approves First CAR-T for Chronic Lymphocytic Leukemia - 6 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 9 months ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - 9 months ago Non-Covalent BTK Inhibitor Approved for CLL - 10 months ago
8	Rick Lange, MD, Texas Tech; Elizabeth Tracey MedPage Today Texas Tech University System, advancing higher education and health care. Lubbock, Texas higher educationhealth care	GLP-1 Agonists in Adolescents and Young Adults; Benefits of Cancer Drug Trials - 4 months ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 7 months ago
10	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	Pivotal Phase III Trials to Evaluate Four Promising Agents in Merck's Oncology, Hematology Pipeline - 9 months ago FDA Approves Lilly's Jaypirca for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma - 10 months ago FDA Grants Priority Review to Expand Indication for Bristol Myers Squibb’s Breyanzi in CLL, SLL - 10 months ago

Journalists covering DLBCL Trials